

DAVID L. PEARLE, M.D.

PERSONAL INFORMATION

HOME ADDRESS: 8709 Bellwood Road
Bethesda, Maryland 20817

BUSINESS TELEPHONE: (202) 444-8833 / (202) 444-1839 FAX

EMAIL ADDRESS: pearled@gunet.georgetown.edu

BIRTH DATE: September 3, 1942

BIRTHPLACE: Pittsburgh, Pennsylvania

CITIZENSHIP: U.S.A.

MARITAL STATUS: Married, two children

EDUCATION

1964 B.A., Amherst College, cum laude
1965 Amherst, Massachusetts

1968 M.D., Harvard Medical School,
Boston, Massachusetts

TRAINING/ PROFESSIONAL POSITIONS

1968-1969 Internship in Medicine, New York Hospital

1969-1970 Residency in Medicine, New York Hospital

1970-1972 Commissioned Officer, Public Health Service (Military Service)
Clinical Instructor of Medicine, George Washington University Hospital, Washington, DC

1972-1974 Cardiology Fellow, Georgetown University Hospital, Washington, DC

July 1974-January 1975 1970 Hemodynamics Fellow, Washington Veterans Administration Hospital Washington, DC

February 1975-June 1975	Staff Cardiologist, Washington Veterans Administration Hospital, Washington, DC
July 1975-March 1983	Staff Cardiologist, Georgetown University Hospital, Washington, DC Assistant Director, Coronary Care Unit, Georgetown University Hospital, Washington, DC
April 1983-June 1989	Co-Director, Medical Special Care Unit, Georgetown University Hospital, Washington, DC
April 1987-1989	Transplant Cardiologist, Georgetown University Hospital, Washington, DC
July 1988-January 1993	Acting Chief, Division of Cardiology, Georgetown University Hospital, Washington, DC
1990-2002	Director, Georgetown Heart Failure Service
October 1995-Present	Director, Coronary Care Unit, Georgetown University Hospital, Washington, DC

APPOINTMENTS

1970	Clinical Instructor of Medicine, George Washington University Hospital, Washington, DC
1974	Instructor of Medicine, Georgetown University Hospital, Washington, DC
1975	Assistant Professor of Medicine (Cardiology), Georgetown University Hospital, Washington, DC
1976	Assistant Professor of Medicine and Pharmacology, Georgetown University Hospital, Washington, DC
1980	Associate Professor of Medicine and Pharmacology, Georgetown University Hospital, Washington, DC (Tenured)
1991	Professor of Medicine, Georgetown University Hospital, Washington, DC (Tenured)
2000	Professor of Medicine, Medstar Georgetown University Hospital, Washington, DC

CERTIFICATION

1974	American Board of Internal Medicine
1975	American Board of Internal Medicine, Subspecialty of Cardiovascular Diseases
2000	American Board of Internal Medicine, Subspecialty of Interventional Cardiology

LICENSURE

New York, 1970
District of Columbia, 1972
Virginia, 1995
Maryland, 2003

AWARDS

Special Clinical Fellowship, Washington Heart Association, 1972-1973
Donald Zucker Visiting Professor, Cornell/New York Hospital, 1991
Vicennial Medal, Georgetown University, 1994
Distinguished Alumnus Award, W. Proctor Harvey Society, 1994
Washingtonian Magazine, Top Doctors, 1991-2005
America's Top Physicians, Consumers Research Council of America, 2004-2005

PROFESSIONAL SOCIETIES

- * American Heart Association, National's Capital Affiliate, President 1984-1986
- * Intersociety Commission for Heart Disease Resources
- * Fellow, American College of Cardiology
- * Fellow, American Heart Association, Council on Clinical Cardiology
- * Medical Society of the District of Columbia
- * Fellow, American Federation for Clinical Research
- * Fellow, Society for Cardiac Angiography

HOSPITAL AND MEDICAL CENTER COMMITTEES

- * Chairman, CPR Committee, 1976-1985
- * Intern Selection Committee, Department of Medicine, 1976-1984
- * Institutional Review Board, 1978-1982
- * Search Committee, Pediatrics Chair, 1988
- * University Fiscal Affairs Committee, 1990
- * Faculty Senate, 1988-1991
- * Hospital Capital Equipment Committee, 1989-1993
- * Search Committee, Anesthesia Chair, 1988
- * Medical Center Bylaws and Governance Committee, 1990
- * Department of Medicine Billing Committee, 1992-1996

- * University Faculty Grievance Committee, 1998-2000
- * Chairman, CPR Committee, 1999-Present
- * Division of Cardiology
 - * Executive Committee, 1992
 - * Billing Committee, Chair, 1992
 - * Strategic Planning Committee, 1992
- * Pharmacy and Therapeutics Committee, 1999- Present

RESEARCH GRANTS AWARDED

1. "Chlordiazepoxide for Ventricular Arrhythmias"
American Heart Association, Nation's Capital Affiliate-1975
2. "Nifedipine, Angina, and Myocardial Infarction Study"
Pfizer laboratories-1979-1982
\$72,635
Principal Investigator: David L. Pearle, MD
3. "Nifedipine: To Determine Efficacy in Management of Angina Pectoris"
Pfizer laboratories-1979-1982
Principal Investigator: David L. Pearle, MD
4. "Open, Multi Center Trial of Ibopamine Hydrochloride in Patients with Congestive Heart Failure: Long Term Safety"
Smith, Kline, and French Laboratories- 1984-1987
\$176,490
Principal Investigator: David L. Pearle, MD
5. "Double Blind, Placebo-Controlled, Multi Center Trial of Ibopamine in Patients with Congestive Heart Failure: Invasive Evaluation of Hemodynamic Parameters and Exercise Testing"
Smith, Kline, and French Laboratories- 1985-1987
\$176,490
Principal Investigator: David L. Pearle, MD
6. "Open Safety Trial of Ibopamine with Captopril and Hydralazine: Acute Hemodynamic Study with Short Term Chronic Dosing"
Smith, Kline, and French Laboratories- 1985-1987
\$59,700
Principal Investigator: David L. Pearle, MD
7. "An Optional, Open, Long Term Study of the Effects of Flosequinan 75, 100, or 150 mg q.d. on Safety, Tolerance, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Randomized to the BP1 919 Double Blind Study"
The Boots Company, U.S.A., Inc.
\$25,000
Principal Investigator: David L. Pearle, MD
8. "An Optional, Open-Label, Long Term Study of the Effects of Flosequinan 100 mg Once a Day (with 150 mg/ 100 mg/ 75 mg/ 50 mg up or down titration) on Safety, Tolerability, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Who Have Participated in BPI-934"
The Boots Company, U.S.A., Inc.
\$48,000
Principal Investigator: David L. Pearle, MD
9. "Modern Approach to the Treatment of Hypertension Multi-Center Study (MATH)"
Pfizer, Inc.
\$4,000
Principal Investigator: David L. Pearle, MD

10. "An Open-Label, Compassionate-Use, Long Term Study to Evaluate the of Repeated Daily Oral Doses of Flosequinan in Patients with Congestive Heart Failure"
The Boots Company, U.S.A., Inc.
\$ N/a
Principal Investigator: David L. Pearle, MD
11. "A Multi-Center, Double Blind, Placebo-Controlled Study of the Effects of Manoplax (Flosequinan) 75 mg Twice Daily or 100 mg Once Daily on Duration of Exercise Treadmill Testing and Disease Symptoms for Up to 12 Weeks in Symptomatic Congestive Heart Failure Patients on Angiotensin Converting Enzyme Inhibitors (ACEIs)
The Boots Company, U.S.A., Inc.
\$180,000
Principal Investigator: David L. Pearle, MD
12. "An Invasive Hemodynamic Study of the Effects, Safety, and Tolerability of 75 mg Twice Daily, 100 mg Once Daily, or 150 mg Once Daily Manoplax (Flosequinan) in New York Heart Association Class III or IV Congestive Heart Failure Patients Uncontrolled by Angiotensin Converting Enzyme Inhibitors (ACEIs) and Diuretics"
The Boots Company, U.S.A., Inc.
\$420,000
Principal Investigator: David L. Pearle, MD
13. "A Double Blind, Placebo-Controlled, Parallel Group, Invasive Hemodynamic Study with Manoplax (Flosequinan) 75 mg Twice Daily, or 150 mg Once Daily for Two Weeks in New York Heart Association Class III and IV Congestive Heart Failure Patients Symptomatic on Angiotensin Converting Enzyme Inhibitors, BPI 993"
The Boots Company, U.S.A., Inc.
\$420,700
Principal Investigator: David L. Pearle, MD
14. "An Open-Label, Long Term Study of the Effects of Manoplax (Flosequinan) 50 mg b.i.d. (with 75 mg b.i.d. upward titration or 25 mg b.i.d. downward titration) on Safety, Tolerability, Survival Time and Disease Symptomatology in Congestive Heart Failure Patients Who Have Participated in BPI 993"
The Boots Company, U.S.A., Inc.
\$89, 800
Principal Investigator: David L. Pearle, MD
15. "U.S. Thrombolysis Registry"
Medical Research International
\$ N/a
Principal Investigator: David L. Pearle, MD
16. "Effects of Aminodipine on Exercise Tolerance and Safety in Patients with Chronic, Symptomatic (New York Heart Association Class II-IV) Heart Failure Receiving a Combination of Angiotensin Converting Enzyme Inhibitors, Digoxin, and Diuretics"
Pfizer Laboratories
Funded at \$59,368 Current available \$11,887 (funds stilled owed)
Principal Investigator: David L. Pearle, MD

17. "Long Term Double Blind Evaluation of the Safety of Amlodopine in Patients with Heart Failure (175E)"
Pfizer Laboratories
Funded at \$5,00 Current available- \$4,832
Principal Investigator: David L. Pearle, MD
18. "A Double Blind Multi Center Comparison of Oral Carvedilol b.i.d. with Placebo in the Treatment of Patients with Congestive Heart Failure, New York Heart Association Class III-IV (221)"
Smith, Kline, and Beecham
Funded at \$24,855 (Projected-\$72,000) Current available \$2,622
Principal Investigator: David L. Pearle, MD
19. "A Six Month Double Blind Multi Center Comparison of Oral Carvedilol b.i.d. with Placebo in the Treatment of Patients with Congestive Heart Failure, New York Heart Association Class III-IV (239)"
Smith, Kline, and Beecham 1992
Funded at \$5,145 (Projected-0) Current available \$9,606
Principal Investigator: David L. Pearle, MD
20. "A Two Year, Open Label Multi Center, Safety Study of Twice Daily Oral Carvedilol in Patients with New York Heart Association Class I-IV Congestive Heart Failure (Extension)"
Sponsor: Smith Kline and Beecham
Total Grant Amount: \$22,760
Amount Funded as of June 1995: \$8,535 (Funds due)
Status: Active
Principal Investigator: David L. Pearle, MD
21. Achieve Congestive Heart Failure Investigation and Economic Variable Evaluation with Accupril
Sponsor: Park Davis
Total Grant Amount: \$235/pt.
Amount Funded as of June 1995: \$1,250
Status: Active
Principal Investigator: David L. Pearle, MD
22. A Multi Center Double Blind Randomized Parallel Design, Pilot Study to Evaluate the Safety and Tolerability of Losartan Administered in Addition to Enalapril in Patients with Heart Failure Treated Previously with ACE Inhibitors
Sponsor: Merck and Co.
Total Grant Amount: \$45,000
Amount Funded as of June 1995:0
Status: Active
Principal Investigator: David L. Pearle, MD
23. An Open Label Evaluation of Carvedilol in Patients with Chronic Congestive Heart Failure New York Heart Association Class II-IV
Sponsor: Smith Kline and Beecham
Total Grant Amount: \$500/pt.
Amount Funded as of June 1995: 0
Status: Active
Principal Investigator: David L. Pearle, MD

24. A Six-Month Double Blind, Multi Center Evaluation of Oral Carvedilol b.i.d. Compared with Placebo in Patients with New York Heart Association Class III-V
Sponsor: Smith Kline and Beecham
Total Grant Amount: \$82,850
Amount Funded as of June 1995: \$5,145
Status: Closed
Principal Investigator: David L. Pearle, MD
25. A 12-Month Double Blind, Multi Center Comparison of Oral Carvedilol b.i.d. with Mild Congestive Heart Failure New York Heart Association Class II
Sponsor: Smith Kline and Beecham
Total Grant Amount: \$53,795.
Amount Funded as of June 1995: \$9,606
Status: Closed
Principal Investigator: David L. Pearle, MD
26. BEST Beta-Blocker Evaluation of Survival Trial: Bucindolol
Sponsor: National Heart, Lung, and Blood Institute, Va. Coop.
Total Grant Amount: \$120,000
Amount Funded as of June 1995: 0
Status: Active
Principal Investigator: David L. Pearle, MD
27. PRAISE II Prospective Randomized Amlodipine Survival Evaluation
Sponsor: Pfizer, Inc.
Total Grant Amount: to be negotiated
Amount Funded as of June 1995: 0
Status: Active
Principal Investigator: David L. Pearle, MD
28. VEST Vesnarinone Trial
Sponsor: Otsuka Pharmaceuticals.
Total Grant Amount: \$78,750
Amount Funded as of June 1995: 0
Status: Active
Principal Investigator: David L. Pearle, MD
29. The Effect of RO-40 on Exercise Treadmill Test Duration and AI Cause Mortality in Patients with Chronic Congestive Heart Failure New York Heart Association Class II-V Treated for Approximately 3-Years
Sponsor: Hoffman LaRoche
Total Grant Amount: \$128,292
Amount Funded as of April 1995: 0
Status: Closed
Principal Investigator: David L. Pearle, MD

Abstracts

Pearle, D.L., Corr, P.B., and R.A Gillis. Influences of site of cardiovascular changes induced by coronary ligation. *Federal Process* 33:162, 1974

Pearle, D.L., and R.A Gillis. Effects of digitalis on the response of ventricular pacemakers to sympathetic nerve stimulation. *Am J Cardiology* 3:162, 1974.

Pearle, D.L., T. Hoekman, K.M. Kent, and R.A Gillis. Pharmacological analysis of a cardiac sympathetic neural response resistant to beta-adrenergic blockage. *Circulation* 50: 111-37, Supplement III, 1974.

Corr, P.B., D.L., Pearle, and R.A Gillis. Occlusion site as a determinant of the deleterious effects of atropine in experimental myocardial infarction. *Am J Cardiology* 35:129, 1975.

Pearle, D.L., Williford, and R.A Gillis. Comparison of practolol and propranolol on coronary occlusion-induced ventricular fibrillation. *Am J Cardiology* 41:399, 1978.

Chizner, M.D., D.L., Pearle, and A.C. deLeon Jr. Natural history of aortic stenosis in adults. *Chest* 74:3322, 1978.

Pearle, D.L., J. Dias Souza, and R.A Gillis. Comparative vagolytic effects of procainamine and n-acetylprocainamide in the dog. *Clinical Research* 27:139 A, 1979.

Alexander, G.J., J. Dias Souza, S.A. Segal, D.L., Pearle and R.A Gillis. Experimental coronary artery spasm: Prevention by nisoldipine and nifedipine by not by verapamil. *Clinical Research*, April 1983.

Muller, J., J. Morrison, P. Stone, R. Rude, B. Rosner, R. Roberts, D.L., Pearle, Z. Turi, J. Schneider, D. Serfas, C. Hennekens, E. Braunwald. Nifedipine therapy for threatened and acute myocardial infarction: A randomized double blind comparison. *Circulation* 68:111-120, 1983.

Muller, J., Z. Turi, D.L., Pearle, J. Schneider, D. Serfas, J. Morrison, P. Stone, R. Rude, B. Rosner, E. Scheiner, R. Roberts, B. Sovel, C. Hennekens, E. Braunwald. Nifedipine vs. conventional therapy for unstable angina pectoris: A randomized double blind comparison. *JACC* 3: 551, 1984.

Gatti, P.J., J. Dias Souza, J.A. Quest, P. Hamosh, D.L., Pearle, R.A Gillis. Ventricular tachyarrhythmias induced by exciting cell bodies in the area postrema of the cat. *Clinical Research* 32:167A, 1984.

Satler, L.F., D.L., Pearle, A.A. Del Negro, K.M. Kent, S. Levine, C.E. Rackley. Reason for low hospital mortality after thrombolysis. *Clinical Research* 32:681A, 1984.

Satler, L.F., C.E. Green, D.L., Pearle, R.S. Pallas, A.A. Del Negro, K.M. Kent, R.D. Fletcher, C.E. Rackley. The importance of metabolic support of the left ventricle after coronary thrombolysis. *JACC* 5:413, 1985.

Krucoff, M.W., C.E. Green, L.F. Satler, F.C. Miller, R.S. Pallas, D.L., Pearle, K.M. Kent, R.D. Fletcher, C.E. Rackley. ST segment monitoring as a predictor of thrombolysis in acute myocardial infarction. *JACC* 5:522, 1985.

Pallas, R.S., L.F. Satler, D.L., Pearle, K.M. Kent, A.A. Del Negro, C.E. Green, C.E. Rackley. Clinical course of patients undergoing emergency angiography during acute myocardial infarction. *Clinical Research* 32:831A, 1984.

Pearle, D.L., L.F. Satler, K.M. Kent, A.A. Del Negro, N.M. Katz, R.B. Wallace, C.E. Rackley. The financial costs of intra coronary thrombolysis. *Clinical Research* 32:83A, 1984.

Satler, L.F., N.M. Katz, K.M. Kent, D.L., Pearle, A.A. Del Negro, C.E. Rackley, R.B. Wallace. Short term mortality for coronary revascularization in the high-risk patient. *Clinical Research* 32:832A, 1984.

Krucoff, M.W., C.E. Green, D.L., Pearle, F.C. Miller, R.S. Pallas, A.A. Del Negro, K.M. Kent, R.D. Fletcher, C.E. Rackley. Successful thrombolysis predicted by ST segment monitoring. *Clinical Research* 32:830A, 1984.

Krucoff, M.W., C.E. Green, L.F. Satler, F.M. Miller, R.S. Pallas, D.L., Pearle, R.D. Fletcher, C.E. Rackley. The use of Holter monitoring to identify subtotal coronary occlusions. *Clinical Research* 32:675A, 1984.

Satler, L.F., C.E. Green, D.L., Pearle, S. Levine, A.A. Del Negro, K.M. Kent, C.E. Rackley. The effects of glucose-insulin-potassium on left ventricle function after coronary thrombolysis. *Clinical Research* 32:681A, 1984.

Satler, L.F., N.M. McNamara, R.S. Pallas, K.M. Kent, D.L., Pearle, C.E. Green, A.A. Del Negro, C.E. Rackley. Intravenous streptokinase for acute myocardial infarction during emergency ambulance transfer. *Clinical Research* 32:682A, 1984.

Pallas, R.S., C.E. Green, L.F. Satler, D.L., Pearle, A.A. Del Negro, K.M. Kent, S. Levine, C.E. Rackley. Coronary collateral incidence and its association with multi vessel disease during acute myocardial infarction. *Clinical Research* 32:679A, 1984.

Satler, L.F., C.E. Green, D.L., Pearle, S. Levine, A.A. Del Negro, K.M. Kent, C.E. Rackley. The beneficial effects of glucose-insulin-potassium therapy during acute thrombolysis. *Circulation* 70:11-153, 1984.

Satler, L.F., W.J. Rogers, K.M. Kent, L.M. Fox, H. A. Goldstein, R.S. Pallas, A.A. Del Negro, D.L., Pearle, C.E. Rackley. Demonstration of salvaged myocardium after successful coronary reperfusion. *Clinical Research* 33:747A, 1985.

Fletcher, A.M., L.F. Satler, R.S. Pallas, S.W. Ahemed, K.M. Kent, D.L., Pearle, C.E. Rackley. Therapy and cost in patients over 65 years of age hospitalized for acute myocardial infarction. *Clinical Research* 33:740A, 1985.

Satler, L.F., R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, N.M. Katz, R. B. Wallace, C.E. Rackley. Frequency of coronary angioplasty and coronary bypass after thrombolytic therapy. *Clinical Research* 33:224A, 1985.

McNamara, N.M., L.F. Satler, R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, C.E. Rackley. Bleeding complications of thrombolytic therapy. *Clinical Research* 33:211A, 1985.

Satler, L.F., C.E. Green, R.S. Pallas, D.L., Pearle, A.A. Del Negro, C.E. Rackley, K.M. Kent. Demonstration of salvaged myocardium after fibrinolytic therapy with coronary angioplasty. *Clinical Research* 33:224A, 1985.

Pallas, R.S., D.L., Pearle, L.F. Satler, C.E. Green, A.A. Del Negro, K.M. Kent, C.E. Rackley. Angiographic characteristics of stenosis in the infarct-related vessel after streptokinase. *Clinical Research* 33:224A, 1985.

Satler, L.F., C.E. Green, R.S. Pallas, D.L., Pearle, A.A. Del Negro, C.E. Rackley, K.M. Kent. Ischemia during angioplasty after streptokinase: A marker of salvaged myocardium. *Clinical Research* 33:747A, 1985.

Lavelle, J.P., M.L. Leitschuh, L.F. Satler, R.S. Pallas, C.E. Green, A.A. Del Negro, D.L., Pearle, C.E. Rackley, K.M. Kent. Short and long term follow-up for coronary angioplasty in acute myocardial infarction. *Clinical Research* 33:744A, 1985.

McNamara, N.M., L.F. Satler, S. W. Ahemed, A.A. Del Negro, R.S. Pallas, D.L., Pearle, K.M. Kent, C.E. Rackley. Hemorrhagic problems associated with thrombolytic therapy for acute myocardial infarction. *Clinical Research* 33:745A, 1985.

Satler, L.F., R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, N.M. Katz, R.B. Wallace, C.E. Rackley. Hospital course after streptokinase: Frequency of coronary angioplasty and coronary bypass. *Clinical Research* 33:747A, 1985.

Pearle, D.L., R.S. Pallas, L.F. Satler, C.E. Green, A.A. Del Negro, K.M. Kent, C.E. Rackley. The incidence of normal or near-normal infarct-related vessels after streptokinase for myocardial infarction. *Clinical Research* 33:173A, 1986.

Fletcher, A.M., L.F. Satler, R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, C.E. Rackley. Final treatment after thrombolytic therapy for infarction. *Clinical Research* 34:169A, 1986.

Lavelle, J.P., L.F. Satler, R.S. Pallas, C.E. Green, A.A. Del Negro, D.L., Pearle, C.E. Rackley, K.M. Kent. Coronary angioplasty for acute myocardial infarction: short and long term follow up. *Clinical Research* 34:172A, 1986.

Pallas, R.S., L.F. Satler, D.L., Pearle, C.E. Green, A.A. Del Negro, K.M. Kent, C.E. Rackley. Infarct vessel residual stenosis and feasibility of coronary angioplasty after streptokinase. *Clinical Research* 34:173A, 1986.

McNamara, N.M., L.F. Satler, S.W. Ahmed, A.A. Del Negro, R.S. Pallas, D.L., Pearle, K.M. Kent, C.E. Rackley. Bleeding complication after streptokinase for acute myocardial infarction. *Clinical Research* 34:209A, 1986.

Satler, L.F., K.M. Kent, L.M. Fox, H.A. Goldstein, W.J. Rogers, R.S. Pallas, A.A. Del Negro, D.L., Pearle, C.E. Rackley. The effects of thrombolytic therapy on inotropic contractile reserve. *Clinical Research* 34:209A, 1986.

Fletcher, A.M., L.F. Satler, R.S. Pallas, C.E. Green, D.L., Pearle, A.A. Del Negro, K.M. Kent, C.E. Rackley. Hospital therapy after streptokinase infusion for infarction. *Clinical Research* 34:298A, 1986.

Pallas, R.S., L.F. Satler, D.L., Pearle, C.E. Green, A.A. Del Negro, K.M. Kent, C.E. Rackley. Feasibility for coronary angioplasty after thrombolysis. *Clinical Research* 34:334A, 1986.

McNamara, N.M., L.F. Satler, S.W. Ahmed, A.A. Del Negro, R.S. Pallas, D.L., Pearle, K.M. Kent, C.E. Rackley. Bleeding with streptokinase: Implications for therapy. *Clinical Research* 34:325A, 1986.

Packer, M., K.A. Narahara, U. Elkayam, J.M. Sullivan, D.L., Pearle, B.M. Massie, M.A. Creager (on behalf of the Principal Investigators of the REFLECT study. Mount Sinai School of Medicine, New York, NY). Randomized, Multi Center, double blind, placebo-controlled study of the efficacy of flosequinan, a new, long-acting vasodilator drug in patients with chronic heart failure. *Supplement to Circulation* 82:111-323, October, 1990.

Publications

Gillis, R.A., D.L., Pearle, and T. Hokeman. Failure of beta adrenergic receptor blockage to prevent arrhythmias induced by cardiac sympathetic nerve stimulation. *Science* 185:70, 1974.

Pearle, D.L., and R.A. Gillis. Effects of digitalis on the response of the ventricular pacemaker to sympathetic neural stimulation and to isoproterenol. *American Journal of Cardiology* 34:704, 1974.

Gillis, R.A., D.L., Pearle, and B. Levitt. Digitalis: A neuro-excitatory drug. *Circulation* 52:379, 1975.

Corr, P.B., D.L., Pearle, and R.A. Gillis. Coronary occlusion site as a determinant of the cardiac rhythm effects of atropine and vagotomy. *American Heart Journal* 92:741, Dec. 1976.

Corr, P.B., D.L., Pearle, J.R. Hinton, W.C. Roberts, and R.A. Gillis. Site of myocardial infarction-a determinant of the cardiovascular changes induced in the cat by coronary occlusion. *Circulation Research* 39:840, Dec. 1976.

Gillis, R.A., P.B. Corr, D.G. Pace, D.E. Evans, J. A. DiMicco, and D.L., Pearle. Role of the nervous system in experimentally induced arrhythmias. *Cardiology* 61:37, 1976.

DiMicco, J.A., R. Prestel, D.L., Pearle, and R.A. Gillis. Mechanism of cardiovascular changes produced in cats by activation of the central nervous system with picrotoxin. *Circulation Research* 41:446, Oct. 1977.

Pearle, D.L., D.J. Williford, and R.A. Gillis. Superiority of protocol versus propranolol in protection against ventricular fibrillation induced by coronary occlusion. *American Journal of Cardiology* 42:960, 1978.

Pearle, D.L. Clinical experience with nifedipine for coronary artery spasm. *Medical Times* 107:12, Dec. 1979.

Chizner, M.D., D.L., Pearle, and A.C. deLeon, Jr. Natural history of aortic stenosis in adults. *American Heart Journal* 99:419-424, April, 1980.

Segal, S.A., D.L., Pearle, and R.A. Gillis. Coronary spasm produced by picrotoxin in cats. *European Journal of Pharmacology* 76: 447-451, 1981.

Pearle, D.L., J. Dias Souza, and R.A. Gillis. Comparative vagolytic effects of procainamide and n-acetylprocainamide in the dog. *Journal of Cardiovascular Pharmacology*, 5:450-453, 1983.

Pearle, D.L. Clinical experience with nifedipine for coronary artery spasm. *Resident & Staff Physician* 26:4, 1979.

Muller, J.E., Z.G. Turi, D.L., Pearle, J.F. Schneider, D.H. Serfas, J. Morrison, P.H. Stone, R.E. Ruide, B. Rosner, B.E. Sobel, C. Tate, E. Scheiner, R. Roberts, C.H. Hennekens, and E. Braunwald. Nifedipine and conventional therapy for unstable angina pectoris: A randomized double blind comparison. *Circulation* 69:728-739, 1984.

Muller, J.E., J. Morrison, P.H. Stone, R.E. Rude, B. Rosner, R. Roberts, D.L., Pearle, Z.G. Turi, J.F. Schneider, D.H. Serfas, C. Tate, E. Scheiner, , B.E. Sobel, C.H. Hennekens, and E. Braunwald. Nifedipine therapy for patients with threatened and acute myocardial infarction: A randomized, double blind, placebo-controlled comparison. *Circulation* 69:740-747, 1984.

Satler, L.F., S. Levine, A.A. Del Negro, D.L., Pearle, K.M. Kent, and C.E. Rackley. Non-surgical coronary reperfusion in evolving myocardial infarction. *Advances in Internal Medicine* 30:231-242, 1984.

Satler, L.F., D.L., Pearle, S. Levine, C.E. Green, A.A. Del Negro, and C.E. Rackley. Aortic dissection masquerading as acute myocardial infarction: Implication for thrombolytic therapy without cardiac catheterization. *American Journal of Cardiology* 54:1134-1135, Nov 19984.

Pearle, D.L. Nifedipine in acute myocardial infarction. *American Journal of Cardiology* 54:21 E. 1984.

Pearle, D.L. Ischemia Heart Disease: Clinical update. Monograph. Home Study Assessment. *American Academy of Family Physicians* 66, 1984.

Satler, L.F., D.L., Pearle, S. Levine, C.E. Green, A.A. Del Negro, K.M. Kent, and C.E. Rackley. Changing concepts and treatment of unstable myocardial ischemia. *Primary Cardiology* 10:88-94, 1984.

Gillis, R.A., B.I. Lee, and D.L., Pearle. Practical pharmacology of anti-ischemic agents. *Consultant*, 25-27, 68-92, April 1985.

Satler, L.F., C.E. Rackley, D.L., Pearle, R.D. Fletcher, and A.A. Del Negro. Total inhibition of a physiologic pacing system due to antipacemaker-mediated tachycardiac mode. *PACE* 8:806-810, 1985.

Satler, L.F., K.M. Kent, C.E. Green, D.L., Pearle, R.S. Pallas, A.A. Del Negro, and C.E. Rackley. Thrombolysis in acute myocardial infarction. In *Advances in Critical Care Cardiology*. Philadelphia: F.A. Davis Company, 1986:39-52.

Rackley, C.E., L.F. Satler, D.L., Pearle, A.A. Del Negro, R.S. Pallas, and K.M. Kent. The use of hemodynamic measurements for the management of acute myocardial infarction. . In *Advances in Critical Care Cardiology*. Philadelphia: F.A. Davis Company, 1986:3-15.

Satler, L.F., C.E. Rackley, C.E. Green, R.S. Pallas, D.L., Pearle, A.A. Del Negro, and K.M. Kent. Ischemia during angioplasty after streptokinase: A marker of myocardial salvage. *American Journal of Cardiology* 56:749-752, 1985.

Krucoff, M.W., C.E. Green, L.F. Satler, F.C. Miller, R.S. Pallas, K.M. Kent, A.A. Del Negro, D.L., Pearle, R.D. Fletcher, and C.E. Rackley. Noninvasive detection of coronary artery patency using continuous ST segment monitoring. *American Journal of Cardiology* 57:916-922, 1986.

Satler, L.F., K.M. Kent, L.M. Fox, C.E. Green, W.J. Rogers, R.S. Pallas, A.A. Del Negro, D.L., Pearle, and C.E. Rackley. The assessment of contractile reserve after thrombolytic therapy for acute myocardial infarction. *American Heart Journal* 111:821-825, 1986.

Rackley, C.E., L.F. Satler, M.W. Krucoff, R.S. Pallas, D.L., Pearle, A.A. Del Negro, and K.M. Kent. Future directions for the diagnosis and treatment of acute myocardial infarction. In: R.H. Cox, ed. *Acute Myocardial Infarction*. New York: Praeger Publisher, Inc. in press.

Pearle, D.L. and C.E. Rackley. Beta-blockers and calcium channel blocking agents in acute myocardial infarction. In *Advances in Critical Care Cardiology*. Philadelphia: F.A. Davis Company, 1986:29-38.

Katz, N.M., T.E. Kubanick, S.W. Ahmed, C.E. Green, D.L., Pearle, L.F. Satler, C.E. Rackley, and R.B. Wallace. Determinants of cardiac failure after coronary bypass surgery within 30 days of acute myocardial infarction.

Satler, L.F., C.E. Green, K.M. Kent, R.S. Pallas, D.L., Pearle, and C.E. Rackley. Metabolic support during coronary reperfusion. *American Heart Journal* 114:54-58, 1987.

Satler, L.F., R.S. Pallas, O.B. Bond, C.E. Green, D.L., Pearle, G.L. Schaer, K.M. Kent, and C.E. Rackley. Assessment of the residual coronary arterial stenosis after thrombolytic therapy during acute myocardial infarction. *American Journal of Cardiology* 59:1231-1233, 1987.

Satler, L.F., C.E. Green, N.M. McNamara, J.P. Lavelle, R.S. Pallas, D.L., Pearle, K.M. Kent, and C.E. Rackley. Late angiographic follow-up after successful thrombolysis and angioplasty. *American Journal of Cardiology* 60:210-213, 1987.

Bowman, M.A., and D.L., Pearle. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. *Journal of Continuing Education Health Professional* 8:13-20, 1988.

Pearle, D.L., Calcium antagonist in acute myocardial infarction. *American Journal of Cardiology* 61:22B-25B, 1988.

Satler, L.F., D.L., Pearle, and C.E. Rackley. Reduction in coronary heart disease: Anatomical considerations. *Clinical Cardiology* 12:422-426, 1989.

Katz, N., P. Pierce, R. Anzeck, M. Visner, H. Canter, M. Forgh, D.L., Pearle, C.M. Tracy, and A. Rahman. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. *The Journal of Heart Transplantation*, 9:14-17, Jan/Feb, 1990.

Pearle, D.L., Pharmacological management of ischemic heart disease with B-blockers and calcium channel blockers. American Heart Journal 120:739-742, September, 1990.

Packer, M., Narahara K.A., Elkayam U., Sullivan J.M., D.L., Pearle, Massie, B.M., and Creager, M.A. Double blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Journal American College of Cardiology, 22(1):65-72, July, 1993.

Coughlin, S.S., D.L., Pearle, K.L. Baughman, A. Wasserman, and M.C. Tefft Diabetes mellitus and the risk of idiopathic dilated cardiomyopathy. Annals of Epidemiology, 4:45-52, 1994.

Pearle, D.L. and DiBianco, R. Clinical Approach to Heart Failure in Classic Teachings in Teachings in Clinical Cardiology, Laennec Publishing, 1996.

Antman EM., Anbe DT; Armstrong PW; Bates ER; Green LA; Hand M; Hochman JS; Krumholz HM; Kushner FG; Lamas GA; Mullany CJ; Ornato JP; Pearle DL; Sloan MA; Smith SC Jr; ACC/AHA Guidelines for the Management of Patients With ST- Elevation Myocardial infarction-Executive Summary. J AM Coll Cardiol 2004;44: 671-719.

Antman EM; Anbe DT; Armstrong PW; Bates ER; Green LA; Hand M; Hochman JS; Krumholz HM; Kushner FG; Lamas GA; Mullany CJ; Ornato JP; Pearle DL; Sloan MA; Smith SC JR; ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction Executive Summary. Circulation. 2004;110:588-636